Review article · 2021 · Open access

Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design

Araceli Rivera-Ordaz, Valeria Peli, Paolo Manzini, Mario Barilani, Lorenza Lazzari

BioDrugs, 35(6), 693–714 · Published 1 November 2021 · DOI 10.1007/s40259-021-00503-9

Open PDFView at the publisherCite this paper

In brief

“Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design” is a 2021 review article by Araceli Rivera-Ordaz and 4 co-authors, published in BioDrugs. OpenAlex counts 47 citations as of 21 November 2026, which puts it in the top 8% of works published in 2021 by citations. It is open access under a CC BY-NC licence: the full text is free to read at BioDrugs.

Citations
47
Most cited in
2026 (15)
Field-weighted impact
0.53
References
134
Authors
5

Abstract

Human induced pluripotent stem cells (hiPSCs) are manufactured as advanced therapy medicinal products for tissue replacement applications. With this aim, the feasibility of hiPSC large-scale expansion in existing bioreactor systems under current good manufacturing practices (cGMP) has been tested. Yet, these attempts have lacked a paradigm shift in culture settings and technologies tailored to hiPSCs, which jeopardizes their clinical translation. The best approach for industrial scale-up of high-quality hiPSCs is to design their manufacturing process by following quality-by-design (QbD) principles: a scientific, risk-based framework for process design based on relating product and process attributes to product quality. In this review, we analyzed the hiPSC expansion manufacturing process implementing the QbD approach in the use of bioreactors, stressing the decisive role played by the cell quantity, quality and costs, drawing key QbD concepts directly from the guidelines of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rivera-Ordaz, A., Peli, V., Manzini, P., Barilani, M., & Lazzari, L. (2021). Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design. BioDrugs, 35(6), 693–714. https://doi.org/10.1007/s40259-021-00503-9

MLA 9

Rivera-Ordaz, Araceli, et al. “Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design.” BioDrugs, vol. 35, no. 6, 2021, pp. 693–714. https://doi.org/10.1007/s40259-021-00503-9.

Chicago

Rivera-Ordaz, Araceli, Valeria Peli, Paolo Manzini, Mario Barilani, and Lorenza Lazzari. 2021. “Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design.” BioDrugs 35 (6): 693–714. https://doi.org/10.1007/s40259-021-00503-9.

Harvard

Rivera-Ordaz, A. et al. (2021) ‘Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design’, BioDrugs, 35(6), pp. 693–714. doi:10.1007/s40259-021-00503-9.

IEEE

A. Rivera-Ordaz, V. Peli, P. Manzini, M. Barilani, and L. Lazzari, “Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design,” BioDrugs, vol. 35, no. 6, pp. 693–714, 2021, doi: 10.1007/s40259-021-00503-9.

BibTeX

@article{riveraordaz2021critical,
  title     = {{Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design}},
  author    = {Rivera-Ordaz, Araceli and Peli, Valeria and Manzini, Paolo and Barilani, Mario and Lazzari, Lorenza},
  journal   = {BioDrugs},
  year      = {2021},
  volume    = {35},
  number    = {6},
  pages     = {693--714},
  doi       = {10.1007/s40259-021-00503-9},
  url       = {https://doi.org/10.1007/s40259-021-00503-9}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
202366
20241414
20251010
20261515

Its field-weighted citation impact is 0.53: it has been cited 0.53 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • human induced pluripotent stem cells
  • bioreactors
  • quality by design
  • cGMP production
  • advanced therapy medicinal products
  • process scale-up
  • ICH guidelines
  • clinical translation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Rivera-Ordaz, A., Peli, V., Manzini, P., Barilani, M., & Lazzari, L. (2021). Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design. BioDrugs, 35(6), 693–714. https://doi.org/10.1007/s40259-021-00503-9

How many times has this paper been cited?

47 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at BioDrugs: sign in and open the PDF from this page.

Who wrote this paper?

Araceli Rivera-Ordaz, Valeria Peli, Paolo Manzini, Mario Barilani, Lorenza Lazzari.

What is the DOI of this paper?

10.1007/s40259-021-00503-9, permanently at https://doi.org/10.1007/s40259-021-00503-9. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.